Novel vaccines for glioblastoma: clinical update and perspective
/in Dendritic Cells, Glioblastoma, International Publications /von 2016-11-01 / Immunotherapy 2016 11;8(11):1293-1308Advances in immunotherapy for the treatment of glioblastoma
/in Glioblastoma, International Publications /von 2016-10-14 / J. Neurooncol. 2017 01;131(1):1-9Mesenchymal stem cells enhance the oncolytic effect of Newcastle disease virus in glioma cells and glioma stem cells via the secretion of TRAIL
/in Glioblastoma, International Publications, Newcastle Disease Virus /von 2016-10-10 / Stem Cell Res Ther 2016 10;7(1):149Phase I/II trial of combination of temozolomide chemotherapy and immunotherapy with fusions of dendritic and glioma cells in patients with glioblastoma
/in Dendritic Cells, Glioblastoma, International Publications /von 2016-09-29 / Cancer Immunol. Immunother. 2016 12;65(12):1499-1509Advances and challenges: dendritic cell vaccination strategies for glioblastoma
/in Dendritic Cells, Glioblastoma, International Publications /von 2016-08-10 / Expert Rev Vaccines 2017 01;16(1):27-36PD-1 blockade enhances the vaccination-induced immune response in glioma
/in Checkpoint-Inhibitors, Dendritic Cells, Glioblastoma, International Publications /von 2016-07-07 / JCI Insight 2016 Jul;1(10)Immunological Aspects of Malignant Gliomas
/in Dendritic Cells, Glioblastoma, International Publications /von 2016-07-01 / Can J Neurol Sci 2016 Jul;43(4):494-502Association of increased survival in glioblastoma patients treated with dendritic cell vaccinations and temozolomide with increased activity of NK cells and ABCC3 expression.
/in Dendritic Cells, Glioblastoma, International Publications /von 2016-06-04 / J Clin Oncol 34, 2016 (suppl; abstr 2039)Emerging immunotherapies for glioblastoma
/in Checkpoint-Inhibitors, Dendritic Cells, Glioblastoma, International Publications, Newcastle Disease Virus /von 2016-06-01 / Expert Opin Emerg Drugs 2016 Jun;21(2):133-45
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Das IOZK
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- Recent developments in targeting breast cancer stem cells (BCSCs): a descriptive review of therapeutic strategies and emerging therapies
- Neoantigen-targeted dendritic cell vaccination in lung cancer patients induces long-lived T cells exhibiting the full differentiation spectrum
- Individualized Multimodal Immunotherapy (IMI): Scientific Rationale and Clinical Experience from a Single Institution